Margarida Maia, PhD,  science writer—

Margarida is a biochemist (University of Porto, Portugal) with a PhD in biomedical sciences (VIB and KULeuven, Belgium). Her main interest is science communication. She is also passionate about design and the dialogue between art and science.

Articles by Margarida Maia

Cognition-targeted Exercise May Boost CBT’s Easing of Fatigue

Cognition-targeting exercise, when combined with cognitive behavioral therapy (CBT) — a type of talk therapy — may further ease fatigue and other symptoms in people with multiple sclerosis (MS), a study found. The study, “The added value of cognition-targeted exercise versus symptom-targeted exercise for multiple sclerosis fatigue: A randomized…

Cortrophin Gel Now Available in US at AllianceRx Walgreens Prime

Cortrophin Gel (repository corticotropin injection), an injectable gel medication approved for acute flares in multiple sclerosis (MS) and other chronic autoimmune diseases, is now available through the AllianceRx Walgreens Prime specialty pharmacy to patients living in the U.S. First approved by the U.S. Food and Drug Administration (FDA)…

Sensorimotor Exercise Linked to Better Overall Quality of Life

Sensorimotor exercise, which aims to improve the neuromuscular system with reduced pressure interventions, such as robotic-assisted training or aquatic exercises, was found to have the greatest total benefits on both mental and physical health-related quality of life (HRQoL) among people with multiple sclerosis (MS). However, aerobic exercises — such…

OTC Melatonin Improves Sleep Quality in MS Patients, Trial Finds

Taking the hormone melatonin may increase overall sleep quality in people with multiple sclerosis (MS), a clinical trial found. The compound, available as an over-the-counter dietary supplement, was particularly effective at extending sleep time in patients. Of note, sleep time decreased with age, meaning that “younger participants may have…

Mynd Tests MAP, Blood Biomarker for MS Diagnosis

Mynd Diagnostics is launching a clinical study to test the ability of a blood biomarker, which the company coined Mynd anti-inflammatory peptide (MAP), to help in the diagnosis and monitoring of multiple sclerosis (MS). Starting in the first quarter of 2022, the company will collect blood samples from diagnosed patients…

COVID-19 Vaccine Side Effects With MS Similar to Public at Large

Side effects upon receiving the COVID-19 vaccine in people with multiple sclerosis (MS) are similar to those reported in the general population, and patients on certain disease-modifying therapies are less likely to have vaccine reactions, a survey-based study found. The findings provide “a reassuring picture” for those who feel hesitant about…

Analysis Finds Acthar Gel Cost-effective for MS Relapses

Acthar Gel (repository corticotropin injection) was found to be a cost-effective treatment for people with multiple sclerosis (MS) experiencing a relapse, according to an economic analysis. Notably, the economic value of Acthar Gel was greater than that of alternative treatments — plasmapheresis and intravenous immunoglobulin — from the…

Owlytics’ MS Smartwatch Goes Through First Validation Stage

Owlytics Healthcare, in partnership with Tel-Aviv Medical Center in Israel, has taken its smartwatch — designed to monitor symptoms of multiple sclerosis (MS) from afar — through a first stage of validation. The smartwatch, worn on the wrist, collects a continuous stream of personal health data that are sent to…

Australian Council Supports Research Into MS Risk Factors, Falls

Australia’s National Health and Medical Research Council (NHMRC) is giving a total of AU$6.75 million (about $5 million) in grants to advance research into multiple sclerosis (MS), including risk factors for the disease, preventing falls, and harnessing viral-immune system interactions to improve patients’ lives. The three investigator grants,…

MS Society to Hold Black MS Experience Summit

The National Multiple Sclerosis Society will host the second edition of its Black MS Experience Summit, a virtual event to help forge connections among those who understand the experience of living with multiple sclerosis (MS) as a Black person. Register here to join the interactive, two-day…

Skin Reactions ‘Frequent’ With Mavenclad, Real-world Study Finds

Skin reactions are common among relapsing-remitting multiple sclerosis (RRMS) patients being treated with oral Mavenclad (cladribine), affecting about one-third of the people evaluated in a real-world study in Germany. These findings suggest the need for careful clinical surveillance to rapidly diagnose and possibly treat skin problems stemming from Mavenclad’s use,…

Impaired Social Cognition May Affect Well-being of RRMS Patients

Impaired social cognition — lacking the ability to understand and process others’ emotions — may affect how people with relapsing-remitting multiple sclerosis (RRMS) feel on a day-to-day basis, a small, three-year study has found. RRMS patients with such difficulties were “characterized at follow-up by a higher level of depression…

PicnicHealth, Komodo Pool Real-world Data for Research

PicnicHealth and Komodo Health have agreed to combine their databases of patient medical records to support research based on real-world evidence. Together, the companies hope to unlock new insights into complex diseases like multiple sclerosis (MS). “Komodo Health and PicnicHealth share a mission to utilize health data…

Repertoire, Yale Working to Identify T-cells Driving MS

Repertoire Immune Medicines and Yale University have entered a research collaboration to identify what type of antigens are activating immune T-cells in patients with multiple sclerosis (MS). Antigens are molecular structures, such as a portion of a protein or a specific chain of sugars, that trigger an immune…

Helper T-cells Drive Transition from RRMS to SPMS, Study Suggests

A group of helper T-cell (Th cells), a type of immune cell, could be responsible for the transition from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive multiple sclerosis (SPMS), with important implications for diagnosing and treating SPMS, a new study found. The study, “Involvement of cytotoxic Eomes-expressing…